Updates in the management of heart failure for the chronic kidney disease patientHsu, Simon; Bansal, NishaCurrent Opinion in Nephrology and Hypertension: May 2019 - Volume 28 - Issue 3 - p 262–266 doi: 10.1097/MNH.0000000000000497 EPIDEMIOLOGY AND PREVENTION: Edited by Navdeep Tangri Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Heart failure is highly prevalent in patients with chronic kidney disease (CKD) and a leading cause of morbidity and mortality in this population. Heart failure therapies proven to benefit the general population may have different risk–benefit profiles in patients with concurrent CKD, plausibly because of the unique pathophysiology of heart failure in this population. The present review highlights recent advances in heart failure treatment as they apply to patients with CKD. Recent findings Several recent publications have shown possible benefits of established heart failure therapies to improve clinical outcomes in patients with CKD; while others conclude neutral or even harmful effects of heart failure therapies in CKD patients. Novel heart failure therapies show promise to improve outcomes in the general population and should be evaluated in future studies to further elucidate the efficacy and safety of these novel therapies specifically in patients with CKD. Summary Knowledge of heart failure treatment to improve clinical outcomes in the CKD population remains limited. Future studies should focus on patients with CKD to evaluate the generalizability of heart failure therapies to this patient population. Department of Medicine/Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington, USA Correspondence to Nisha Bansal, MD, MAS, Division of Nephrology, Kidney Research Institute, University of Washington, 908 Jefferson St, 3rd Floor, Seattle, WA 98104, USA. E-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.